Personalized Oncology Market Size, Share & Trends Analysis Report by Component (Diagnostics, Therapeutics, Software & Digital Platforms, Services), Technology, Cancer Type, Therapy Type, Biomarker Type, Application, End User and Geography (North America, Europe, Asia Pacific, Middle East, Africa and South America) – Global Industry Data, Trends and Forecasts, 2026–2035
|
|
|
Segmental Data Insights |
|
|
Demand Trends |
|
|
Competitive Landscape |
|
|
Strategic Development |
|
|
Future Outlook & Opportunities |
|
Personalized Oncology Market Size, Share, and Growth
The global personalized oncology market is exhibiting strong growth, with an estimated value of USD 7.7 billion in 2025 and USD 18.4 billion by 2035, achieving a CAGR of 9.1%, during the forecast period. Asia Pacific is the fastest-growing personalized oncology market due to rising cancer prevalence, expanding genomic medicine investments, improving healthcare infrastructure, increasing adoption of precision diagnostics, and strong government support for personalized medicine initiatives.
"Developing companion diagnostic claims for the historically important KRAS biomarker will enable broader identification of patients who may benefit from targeted therapies, regardless of tumor origin," said Traci Pawlowski, vice president and head of Clinical Solutions at Illumina. "This marks a critical step forward as we build our clinical offerings to support clinicians and pharmaceutical partners in delivering more personalized, effective, and broadly accessible precision cancer care."
The increasing use of biomarker-based testing and full genome profiling in cancer diagnosis and treatment selection is fueling the personalized oncology market. For instance, in May 2025, Illumina announced TSO Comprehensive test was granted broad reimbursement by payers, thereby helping to democratize comprehensive genomic profiling and enhancing its oncology portfolio for precision oncology and companion diagnostic testing.
In addition, the growing number of partnerships between companion diagnostics and precision medicine is fueling the personalized oncology market by supporting more targeted and therapy-specific development of cancer therapies. For instance, in June 2025, QIAGEN partnered with Incyte to create companion diagnostics for mutant CALR myeloproliferative neoplasms, demonstrating the progression towards more targeted and individualized cancer therapy selection.
Key adjacent opportunities for the global personalized oncology market include liquid biopsy-based early cancer detection, AI-driven diagnostic decision support, pharmaceutical companion diagnostic co-development, bioinformatics and multi-omics data analytics platforms, and real-world evidence solutions for oncology drug optimization, digital pathology platforms, cloud-based genomic infrastructure, and population-scale cancer screening programs supporting precision oncology adoption. These adjacent markets collectively accelerate the shift toward early detection, data-driven oncology care, and highly targeted treatment pathways, significantly expanding the commercial ecosystem of personalized cancer care.
Personalized Oncology Market Dynamics and Trends
Driver: Increasing Clinical Adoption of Molecular Residual Disease Testing Strengthening Personalized Cancer Management
- The personalized oncology market is being propelled by the growing clinical adoption of molecular residual disease (MRD) testing, which allows for the detection of residual cancer after treatment and is used to guide personalized therapy before clinical relapse.
- MRD monitoring allows for tailor-made adjuvant therapy, thus enhancing disease management and decreasing the risk of recurrence. For instance, in January 2026, Natera, Inc. announced new clinical evidence with its Signatera MRD assay to show that the product has greater clinical utility in more indications of solid tumors, for recurrence monitoring and personalized treatment decisions.
- The growing adoption of MRD testing is driving precision diagnostics toward a central role in clinical practice as a tool for oncology, leading to the use of highly sensitive genomic tests for disease monitoring and personalized treatment decisions for a variety of cancer types.
- Growing adoption of MRD is contributing to expanding precision diagnostics and enhancing personalized cancer outcomes.
Restraint: Limited Standardization of Complex Multi-Omic Data Interpretation Across Clinical Laboratories Worldwide
- Interpretation of complex multi-omic data generated from genomic, transcriptomic, proteomic, and epigenomic analyses remains a challenge in the personalized oncology market. The integration of these pipelines, the classification of variants, the reporting of the variants and the laboratory validation protocols often differ with one another, causing inconsistent clinical interpretations and therefore restricting the general uptake.
- For instance, in March 2026, SOPHiA GENETICS upgraded its cloud-based analytics platform to further harmonize genomic interpretation workflows and to promote the reproducibility of molecular analysis in laboratories.
- Incomplete healthcare system harmonization creates operational and regulatory hurdles for implementing individualized oncology diagnostics and precision medicine programs.
- The global scalability of personalized oncology diagnosis remains moderate, due to the interpretation variability.
Opportunity: Expansion of Precision Oncology Clinical Trial Matching Platforms Accelerating Targeted Drug Development
- The personalized oncology market offers strong growth potential due to the increasing adoption of AI-driven clinical trial matching solutions that can match molecularly characterized patients with biomarker-targeted oncology trials. These platforms are helping with patient recruitment, higher enrollment of genetically matched patients and faster advances in creating targeted cancer treatments.
- For instance, in April 2026, Caris Life Sciences expanded molecular profiling capabilities and further developed integration with pharmaceutical partners to the Caris Clinical Trial Solutions platform to further advance biomarker-driven patient identification in oncology clinical trials.
- The growing volume of real-world genomic data and the integration of AI-driven analyses are further enhancing trial optimization, which accelerates therapy development and allows broad implementation of precision medicine in oncology trials.
- AI-powered trial matching accelerates targeted therapy development and enhances precision medicine commercialization.
Key Trend: Growing Integration of Digital Pathology Artificial Intelligence with Comprehensive Genomic Profiling Platforms
- The personalized oncology market is increasingly embracing the combination of AI-powered digital pathology with full genome profiling to deliver integrated diagnosis and biomarker identification based on tissue structure and genomic sequencing data, with a view to ensuring better tumor characterization, speeding up clinical decisions, and improving the precision of cancer therapy selection.
- This convergence enhances the accuracy of tumor classification, biomarker discovery, treatment selection and diagnostic accuracy in a shorter time. In May 2025, Paige enhanced its AI-powered pathology platform, boosting its ability to integrate with molecular oncology workflows, which in turn supported biomarker assessment and pathology-driven precision diagnostics.
- Integrated pathology-genomics workflows, within a single laboratory, are increasingly being used by healthcare providers to inform multidisciplinary oncology decision-making, to simplify clinical workflows and to provide more individualized treatment strategies for a variety of cancer types.
- AI pathology and genomics are transforming cancer precision diagnostics and driving fast-paced personalized treatment decisions.
Personalized Oncology Market Analysis and Segmental Data
Breast Cancer Dominate Global Personalized Oncology Market
- The breast cancer segment dominates the global personalized oncology market due to the extensive characterization of the breast cancer tumor type with genetic markers and the rising use of biomarkers like HER2, BRCA, and PIK3CA to inform treatment decisions. Precision medicine has gained strength in both early and metastatic breast cancer due to the ability to use genomic profiling, companion diagnostics and targeted therapies.
- For instance, in September 2025, Roche announced the CE IVDR approval of its VENTANA HER2 (4B5) companion diagnostic to detect patients with HER2-ultralow metastatic breast cancer who could benefit from ENHERTU.
- Innovation and clinical adoption worldwide are being driven by the availability of validated companion diagnostics, increasing molecular testing rates, and a robust pipeline of targeted therapies, which continue to establish breast cancer as the leading application area within personalized oncology.
- Breast cancer's leadership is being strengthened by the ongoing development of biomarker-guided diagnostics and targeted treatments, which is hastening the global adoption of personalized oncology solutions.
North America Leads Global Personalized Oncology Market Demand
- North America leads the personalized oncology market is due to the wide adoption of precision oncology in clinical practice, coupled with well-established genomic testing infrastructure and high adoption of companion diagnostics. For example, in 2026, Tempus AI enhanced its AI-powered precision oncology platform with the expansion of genomic testing and AI-driven clinical decision support to U.S. healthcare providers.
- In addition, sustained investments in national cancer research, genomic medicine, and biomarker-based oncology programs, with strong government support, are driving clinical implementation and innovation in precision medicine. For instance, The National Cancer Institute increased funding for Cancer Moonshot to support precision oncology, molecular profiling and biomarker-driven clinical trials throughout the United States.
- The strong industry innovation, advanced genomic infrastructure, and continued government support are driving the widespread adoption of precision oncology, further positioning North America as a global leader in personalized oncology.
Personalized Oncology Market Ecosystem
The global personalized oncology market is highly consolidated, with leading companies such as F. Hoffmann-La Roche, AstraZeneca PLC, Novartis AG, Thermo Fisher Scientific, and Illumina, maintaining strong market positions through continuous investments in comprehensive genomic profiling, companion diagnostics, next-generation sequencing (NGS), liquid biopsy technologies, and AI-enabled precision medicine platforms. Advanced molecular diagnostics and targeted therapeutic ecosystems are at the core of these companies' efforts to bolster precision cancer care in the clinical and research environments.
Leading companies are improving particular technologies for identifying biomarkers and the selection of personalized therapy. For instance, Roche advances genomic profiling, Illumina adds more power to NGS solutions, Thermo Fisher improves companion diagnostics and AstraZeneca and Novartis are pushing the development of targeted therapies with biomarkers.
The global personalized oncology market is poised for sustainable growth, with the adoption of personalized treatments increasing due to continuous innovations in genomic diagnostics, companion diagnostics, and AI-powered precision medicine.
Recent Development and Strategic Overview:
- In May 2026, Foundation Medicine, Inc. introduced advanced digital solutions to support faster cancer treatment decision-making by enhancing genomic data interpretation and streamlining precision oncology workflows for healthcare providers and biopharmaceutical partners.
- In July 2025, Illumina, Inc. launched TruSight Oncology 500 v2, adding built-in HRD biomarker detection, lower tissue input requirements, and faster turnaround. The upgraded assay improves research-based comprehensive genomic profiling and helps laboratories accelerate oncology biomarker testing and treatment research workflows.
Report Scope
|
Detail |
|
|
Market Size in 2025 |
USD 7.7 Bn |
|
Market Forecast Value in 2035 |
USD 18.4 Bn |
|
Growth Rate (CAGR) |
9.1% |
|
Forecast Period |
2026 – 2035 |
|
Historical Data Available for |
2021 – 2024 |
|
Market Size Units |
US$ Billion for Value |
|
Report Format |
Electronic (PDF) + Excel |
|
North America |
Europe |
Asia Pacific |
Middle East |
Africa |
South America |
|
|
|
|
|
|
|
Companies Covered |
|||||
|
|||||
Personalized Oncology Market Segmentation and Highlights
|
Segment |
Sub-segment |
|
Personalized Oncology Market, By Component |
|
|
Personalized Oncology Market, By Technology |
|
|
Personalized Oncology Market, By Cancer Type |
|
|
Personalized Oncology Market, By Therapy Type |
|
|
Personalized Oncology Market, By Biomarker Type |
|
|
Personalized Oncology Market, By Application |
|
|
Personalized Oncology Market, By End User |
|
Frequently Asked Questions
Table of Contents
- 1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
- 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
- 1.6.1. Open Sources
- 1.6.2. Paid Databases
- 1.6.3. Associations
- 1.7. Primary Research
- 1.7.1. Primary Sources
- 1.7.2. Primary Interviews with Stakeholders across Ecosystem
- 2. Executive Summary
- 2.1. Global Personalized Oncology Market Outlook
- 2.1.1. Personalized Oncology Market Size (Value - US$ Bn), and Forecasts, 2021-2035
- 2.1.2. Compounded Annual Growth Rate Analysis
- 2.1.3. Growth Opportunity Analysis
- 2.1.4. Segmental Share Analysis
- 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
- 2.5.1. Customer/ End-use Industry Assessment
- 2.5.2. Growth Opportunity Data, 2026-2035
- 2.5.2.1. Regional Data
- 2.5.2.2. Country Data
- 2.5.2.3. Segmental Data
- 2.5.3. Identification of Potential Market Spaces
- 2.5.4. GAP Analysis
- 2.5.5. Potential Attractive Price Points
- 2.5.6. Prevailing Market Risks & Challenges
- 2.5.7. Preferred Sales & Marketing Strategies
- 2.5.8. Key Recommendations and Analysis
- 2.5.9. A Way Forward
- 2.1. Global Personalized Oncology Market Outlook
- 3. Industry Data and Premium Insights
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
- 3.1.1. Healthcare & Pharmaceutical Ecosystem Analysis
- 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
- 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
- 3.4. Trade Analysis
- 3.4.1. Import & Export Analysis, 2025
- 3.4.2. Top Importing Countries
- 3.4.3. Top Exporting Countries
- 3.5. Trump Tariff Impact Analysis
- 3.5.1. Manufacturer
- 3.5.1.1. Based on the component & Raw material
- 3.5.2. Supply Chain
- 3.5.3. End Consumer
- 3.5.1. Manufacturer
- 3.6. Raw Material Analysis
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
- 4. Market Overview
- 4.1. Market Dynamics
- 4.1.1. Drivers
- 4.1.1.1. Increasing adoption of comprehensive genomic profiling and next-generation sequencing (NGS)
- 4.1.1.2. Growing use of companion diagnostics and biomarker-guided targeted therapies
- 4.1.1.3. Expanding adoption of liquid biopsy for early cancer detection and disease monitoring
- 4.1.2. Restraints
- 4.1.2.1. High cost of genomic testing and personalized cancer therapies
- 4.1.2.2. Limited standardization in multi-omic data interpretation and clinical validation
- 4.1.1. Drivers
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
- 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
- 4.3.2. Tariffs and Standards
- 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Eco-system Analysis
- 4.5. Porter’s Five Forces Analysis
- 4.6. PESTEL Analysis
- 4.7. Global Personalized Oncology Market Demand
- 4.7.1. Historical Market Size – in Value (US$ Bn), 2020-2024
- 4.7.2. Current and Future Market Size – in Value (US$ Bn), 2026–2035
- 4.7.2.1. Y-o-Y Growth Trends
- 4.7.2.2. Absolute $ Opportunity Assessment
- 4.1. Market Dynamics
- 5. Competition Landscape
- 5.1. Competition structure
- 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
- 5.2.1. Global Company Market Share
- 5.2.2. By Region
- 5.2.2.1. North America
- 5.2.2.2. Europe
- 5.2.2.3. Asia Pacific
- 5.2.2.4. Middle East
- 5.2.2.5. Africa
- 5.2.2.6. South America
- 5.3. Product Comparison Matrix
- 5.3.1. Specifications
- 5.3.2. Market Positioning
- 5.3.3. Pricing
- 5.1. Competition structure
- 6. Global Personalized Oncology Market Analysis, by Component
- 6.1. Key Segment Analysis
- 6.2. Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Component, 2021-2035
- 6.2.1. Diagnostics
- 6.2.1.1. Companion Diagnostics
- 6.2.1.2. Molecular Diagnostic Tests
- 6.2.1.3. Genomic Sequencing Kits
- 6.2.1.4. Liquid Biopsy Tests
- 6.2.1.5. Biomarker Testing Solutions
- 6.2.1.6. Immunohistochemistry (IHC) Assays
- 6.2.1.7. PCR-Based Diagnostic Kits
- 6.2.1.8. Fluorescence in Situ Hybridization (FISH) Assays
- 6.2.1.9. Others
- 6.2.2. Therapeutics
- 6.2.2.1. Targeted Therapy Drugs
- 6.2.2.2. Immuno-Oncology Therapeutics
- 6.2.2.3. Hormonal Therapy Products
- 6.2.2.4. Precision Chemotherapy Solutions
- 6.2.2.5. Cell & Gene Therapy Products
- 6.2.2.6. Personalized Cancer Vaccines
- 6.2.2.7. Combination Therapy Products
- 6.2.2.8. Others
- 6.2.3. Software & Digital Platforms
- 6.2.3.1. Bioinformatics Software
- 6.2.3.2. Clinical Decision Support Software
- 6.2.3.3. Genomic Data Analysis Platforms
- 6.2.3.4. AI-Based Oncology Analytics Software
- 6.2.3.5. Molecular Tumor Board Platforms
- 6.2.3.6. Patient Data Management Software
- 6.2.3.7. Precision Medicine Workflow Software
- 6.2.3.8. Others
- 6.2.4. Services
- 6.2.4.1. Genomic Testing Services
- 6.2.4.2. Biomarker Analysis Services
- 6.2.4.3. Bioinformatics & Data Interpretation Services
- 6.2.4.4. Clinical Consulting Services
- 6.2.4.5. Companion Diagnostic Development Services
- 6.2.4.6. Laboratory Testing Services
- 6.2.4.7. Technical Support & Training Services
- 6.2.4.8. Regulatory & Compliance Services
- 6.2.4.9. Others
- 6.2.1. Diagnostics
- 7. Global Personalized Oncology Market Analysis, by Technology
- 7.1. Key Segment Analysis
- 7.2. Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technology, 2021-2035
- 7.2.1. Next-Generation Sequencing (NGS)
- 7.2.2. Polymerase Chain Reaction (PCR)
- 7.2.3. Immunohistochemistry (IHC)
- 7.2.4. Fluorescence in Situ Hybridization (FISH)
- 7.2.5. Companion Diagnostics
- 7.2.6. Liquid Biopsy
- 7.2.7. AI & Machine Learning
- 7.2.8. Multi-Omics Analysis
- 7.2.9. Bioinformatics
- 7.2.10. Others
- 8. Global Personalized Oncology Market Analysis, by Cancer Type
- 8.1. Key Segment Analysis
- 8.2. Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Cancer Type, 2021-2035
- 8.2.1. Breast Cancer
- 8.2.2. Lung Cancer
- 8.2.3. Colorectal Cancer
- 8.2.4. Prostate Cancer
- 8.2.5. Blood Cancer (Leukemia, Lymphoma & Myeloma)
- 8.2.6. Ovarian Cancer
- 8.2.7. Melanoma
- 8.2.8. Pancreatic Cancer
- 8.2.9. Liver Cancer
- 8.2.10. Gastric Cancer
- 8.2.11. Other Cancers
- 9. Global Personalized Oncology Market Analysis, by Therapy Type
- 9.1. Key Segment Analysis
- 9.2. Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapy Type, 2021-2035
- 9.2.1. Targeted Therapy
- 9.2.2. Immunotherapy
- 9.2.3. Hormone Therapy
- 9.2.4. Chemotherapy
- 9.2.5. Cell & Gene Therapy
- 9.2.6. Combination Therapy
- 9.2.7. Others
- 10. Global Personalized Oncology Market Analysis, by Biomarker Type
- 10.1. Key Segment Analysis
- 10.2. Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Biomarker Type, 2021-2035
- 10.2.1. Genomic Biomarkers
- 10.2.2. Proteomic Biomarkers
- 10.2.3. Transcriptomic Biomarkers
- 10.2.4. Epigenetic Biomarkers
- 10.2.5. Metabolomic Biomarkers
- 10.2.6. Others
- 11. Global Personalized Oncology Market Analysis, by Application
- 11.1. Key Segment Analysis
- 11.2. Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Application, 2021-2035
- 11.2.1. Cancer Diagnosis
- 11.2.2. Treatment Selection
- 11.2.3. Companion Diagnostics
- 11.2.4. Prognostic Assessment
- 11.2.5. Therapy Response Monitoring
- 11.2.6. Disease Recurrence Monitoring
- 11.2.7. Drug Discovery & Development
- 11.2.8. Clinical Research
- 11.2.9. Others
- 12. Global Personalized Oncology Market Analysis, by End User
- 12.1. Key Segment Analysis
- 12.2. Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, by End User, 2021-2035
- 12.2.1. Hospitals
- 12.2.2. Cancer Specialty Centers
- 12.2.3. Diagnostic Laboratories
- 12.2.4. Academic & Research Institutes
- 12.2.5. Pharmaceutical & Biotechnology Companies
- 12.2.6. Contract Research Organizations (CROs)
- 12.2.7. Others
- 13. Global Personalized Oncology Market Analysis, by Region
- 13.1. Key Findings
- 13.2. Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
- 13.2.1. North America
- 13.2.2. Europe
- 13.2.3. Asia Pacific
- 13.2.4. Middle East
- 13.2.5. Africa
- 13.2.6. South America
- 14. North America Personalized Oncology Market Analysis
- 14.1. Key Segment Analysis
- 14.2. Regional Snapshot
- 14.3. North America Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 14.3.1. Component
- 14.3.2. Technology
- 14.3.3. Cancer Type
- 14.3.4. Therapy Type
- 14.3.5. Biomarker Type
- 14.3.6. Application
- 14.3.7. End User
- 14.3.8. Country
- 14.3.8.1. USA
- 14.3.8.2. Canada
- 14.3.8.3. Mexico
- 14.4. USA Personalized Oncology Market
- 14.4.1. Country Segmental Analysis
- 14.4.2. Component
- 14.4.3. Technology
- 14.4.4. Cancer Type
- 14.4.5. Therapy Type
- 14.4.6. Biomarker Type
- 14.4.7. Application
- 14.4.8. End User
- 14.5. Canada Personalized Oncology Market
- 14.5.1. Country Segmental Analysis
- 14.5.2. Component
- 14.5.3. Technology
- 14.5.4. Cancer Type
- 14.5.5. Therapy Type
- 14.5.6. Biomarker Type
- 14.5.7. Application
- 14.5.8. End User
- 14.6. Mexico Personalized Oncology Market
- 14.6.1. Country Segmental Analysis
- 14.6.2. Component
- 14.6.3. Technology
- 14.6.4. Cancer Type
- 14.6.5. Therapy Type
- 14.6.6. Biomarker Type
- 14.6.7. Application
- 14.6.8. End User
- 15. Europe Personalized Oncology Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. Europe Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 15.3.1. Component
- 15.3.2. Technology
- 15.3.3. Cancer Type
- 15.3.4. Therapy Type
- 15.3.5. Biomarker Type
- 15.3.6. Application
- 15.3.7. End User
- 15.3.8. Country
- 15.3.8.1. Germany
- 15.3.8.2. United Kingdom
- 15.3.8.3. France
- 15.3.8.4. Italy
- 15.3.8.5. Spain
- 15.3.8.6. Netherlands
- 15.3.8.7. Nordic Countries
- 15.3.8.8. Poland
- 15.3.8.9. Russia & CIS
- 15.3.8.10. Rest of Europe
- 15.4. Germany Personalized Oncology Market
- 15.4.1. Country Segmental Analysis
- 15.4.2. Component
- 15.4.3. Technology
- 15.4.4. Cancer Type
- 15.4.5. Therapy Type
- 15.4.6. Biomarker Type
- 15.4.7. Application
- 15.4.8. End User
- 15.5. United Kingdom Personalized Oncology Market
- 15.5.1. Country Segmental Analysis
- 15.5.2. Component
- 15.5.3. Technology
- 15.5.4. Cancer Type
- 15.5.5. Therapy Type
- 15.5.6. Biomarker Type
- 15.5.7. Application
- 15.5.8. End User
- 15.6. France Personalized Oncology Market
- 15.6.1. Country Segmental Analysis
- 15.6.2. Component
- 15.6.3. Technology
- 15.6.4. Cancer Type
- 15.6.5. Therapy Type
- 15.6.6. Biomarker Type
- 15.6.7. Application
- 15.6.8. End User
- 15.7. Italy Personalized Oncology Market
- 15.7.1. Country Segmental Analysis
- 15.7.2. Component
- 15.7.3. Technology
- 15.7.4. Cancer Type
- 15.7.5. Therapy Type
- 15.7.6. Biomarker Type
- 15.7.7. Application
- 15.7.8. End User
- 15.8. Spain Personalized Oncology Market
- 15.8.1. Country Segmental Analysis
- 15.8.2. Component
- 15.8.3. Technology
- 15.8.4. Cancer Type
- 15.8.5. Therapy Type
- 15.8.6. Biomarker Type
- 15.8.7. Application
- 15.8.8. End User
- 15.9. Netherlands Personalized Oncology Market
- 15.9.1. Country Segmental Analysis
- 15.9.2. Component
- 15.9.3. Technology
- 15.9.4. Cancer Type
- 15.9.5. Therapy Type
- 15.9.6. Biomarker Type
- 15.9.7. Application
- 15.9.8. End User
- 15.10. Nordic Countries Personalized Oncology Market
- 15.10.1. Country Segmental Analysis
- 15.10.2. Component
- 15.10.3. Technology
- 15.10.4. Cancer Type
- 15.10.5. Therapy Type
- 15.10.6. Biomarker Type
- 15.10.7. Application
- 15.10.8. End User
- 15.11. Poland Personalized Oncology Market
- 15.11.1. Country Segmental Analysis
- 15.11.2. Component
- 15.11.3. Technology
- 15.11.4. Cancer Type
- 15.11.5. Therapy Type
- 15.11.6. Biomarker Type
- 15.11.7. Application
- 15.11.8. End User
- 15.12. Russia & CIS Personalized Oncology Market
- 15.12.1. Country Segmental Analysis
- 15.12.2. Component
- 15.12.3. Technology
- 15.12.4. Cancer Type
- 15.12.5. Therapy Type
- 15.12.6. Biomarker Type
- 15.12.7. Application
- 15.12.8. End User
- 15.13. Rest of Europe Personalized Oncology Market
- 15.13.1. Component
- 15.13.2. Component
- 15.13.3. Technology
- 15.13.4. Cancer Type
- 15.13.5. Therapy Type
- 15.13.6. Biomarker Type
- 15.13.7. Application
- 15.13.8. End User
- 16. Asia Pacific Personalized Oncology Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. Asia Pacific Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 16.3.1. Component
- 16.3.2. Technology
- 16.3.3. Cancer Type
- 16.3.4. Therapy Type
- 16.3.5. Biomarker Type
- 16.3.6. Application
- 16.3.7. End User
- 16.3.8. Country
- 16.3.8.1. China
- 16.3.8.2. India
- 16.3.8.3. Japan
- 16.3.8.4. South Korea
- 16.3.8.5. Australia and New Zealand
- 16.3.8.6. Indonesia
- 16.3.8.7. Malaysia
- 16.3.8.8. Thailand
- 16.3.8.9. Vietnam
- 16.3.8.10. Rest of Asia Pacific
- 16.4. China Personalized Oncology Market
- 16.4.1. Country Segmental Analysis
- 16.4.2. Component
- 16.4.3. Technology
- 16.4.4. Cancer Type
- 16.4.5. Therapy Type
- 16.4.6. Biomarker Type
- 16.4.7. Application
- 16.4.8. End User
- 16.5. India Personalized Oncology Market
- 16.5.1. Country Segmental Analysis
- 16.5.2. Component
- 16.5.3. Technology
- 16.5.4. Cancer Type
- 16.5.5. Therapy Type
- 16.5.6. Biomarker Type
- 16.5.7. Application
- 16.5.8. End User
- 16.6. Japan Personalized Oncology Market
- 16.6.1. Country Segmental Analysis
- 16.6.2. Component
- 16.6.3. Technology
- 16.6.4. Cancer Type
- 16.6.5. Therapy Type
- 16.6.6. Biomarker Type
- 16.6.7. Application
- 16.6.8. End User
- 16.7. South Korea Personalized Oncology Market
- 16.7.1. Country Segmental Analysis
- 16.7.2. Component
- 16.7.3. Technology
- 16.7.4. Cancer Type
- 16.7.5. Therapy Type
- 16.7.6. Biomarker Type
- 16.7.7. Application
- 16.7.8. End User
- 16.8. Australia and New Zealand Personalized Oncology Market
- 16.8.1. Country Segmental Analysis
- 16.8.2. Component
- 16.8.3. Technology
- 16.8.4. Cancer Type
- 16.8.5. Therapy Type
- 16.8.6. Biomarker Type
- 16.8.7. Application
- 16.8.8. End User
- 16.9. Indonesia Personalized Oncology Market
- 16.9.1. Country Segmental Analysis
- 16.9.2. Component
- 16.9.3. Technology
- 16.9.4. Cancer Type
- 16.9.5. Therapy Type
- 16.9.6. Biomarker Type
- 16.9.7. Application
- 16.9.8. End User
- 16.10. Malaysia Personalized Oncology Market
- 16.10.1. Country Segmental Analysis
- 16.10.2. Component
- 16.10.3. Technology
- 16.10.4. Cancer Type
- 16.10.5. Therapy Type
- 16.10.6. Biomarker Type
- 16.10.7. Application
- 16.10.8. End User
- 16.11. Thailand Personalized Oncology Market
- 16.11.1. Country Segmental Analysis
- 16.11.2. Component
- 16.11.3. Technology
- 16.11.4. Cancer Type
- 16.11.5. Therapy Type
- 16.11.6. Biomarker Type
- 16.11.7. Application
- 16.11.8. End User
- 16.12. Vietnam Personalized Oncology Market
- 16.12.1. Country Segmental Analysis
- 16.12.2. Component
- 16.12.3. Technology
- 16.12.4. Cancer Type
- 16.12.5. Therapy Type
- 16.12.6. Biomarker Type
- 16.12.7. Application
- 16.12.8. End User
- 16.13. Rest of Asia Pacific Personalized Oncology Market
- 16.13.1. Country Segmental Analysis
- 16.13.2. Component
- 16.13.3. Technology
- 16.13.4. Cancer Type
- 16.13.5. Therapy Type
- 16.13.6. Biomarker Type
- 16.13.7. Application
- 16.13.8. End User
- 17. Middle East Personalized Oncology Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Middle East Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 17.3.1. Component
- 17.3.2. Technology
- 17.3.3. Cancer Type
- 17.3.4. Therapy Type
- 17.3.5. Biomarker Type
- 17.3.6. Application
- 17.3.7. End User
- 17.3.8. Country
- 17.3.8.1. Turkey
- 17.3.8.2. UAE
- 17.3.8.3. Saudi Arabia
- 17.3.8.4. Israel
- 17.3.8.5. Rest of Middle East
- 17.4. Turkey Personalized Oncology Market
- 17.4.1. Country Segmental Analysis
- 17.4.2. Component
- 17.4.3. Technology
- 17.4.4. Cancer Type
- 17.4.5. Therapy Type
- 17.4.6. Biomarker Type
- 17.4.7. Application
- 17.4.8. End User
- 17.5. UAE Personalized Oncology Market
- 17.5.1. Country Segmental Analysis
- 17.5.2. Component
- 17.5.3. Technology
- 17.5.4. Cancer Type
- 17.5.5. Therapy Type
- 17.5.6. Biomarker Type
- 17.5.7. Application
- 17.5.8. End User
- 17.6. Saudi Arabia Personalized Oncology Market
- 17.6.1. Country Segmental Analysis
- 17.6.2. Component
- 17.6.3. Technology
- 17.6.4. Cancer Type
- 17.6.5. Therapy Type
- 17.6.6. Biomarker Type
- 17.6.7. Application
- 17.6.8. End User
- 17.7. Israel Personalized Oncology Market
- 17.7.1. Country Segmental Analysis
- 17.7.2. Component
- 17.7.3. Technology
- 17.7.4. Cancer Type
- 17.7.5. Therapy Type
- 17.7.6. Biomarker Type
- 17.7.7. Application
- 17.7.8. End User
- 17.8. Rest of Middle East Personalized Oncology Market
- 17.8.1. Country Segmental Analysis
- 17.8.2. Component
- 17.8.3. Technology
- 17.8.4. Cancer Type
- 17.8.5. Therapy Type
- 17.8.6. Biomarker Type
- 17.8.7. Application
- 17.8.8. End User
- 18. Africa Personalized Oncology Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Africa Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 18.3.1. Component
- 18.3.2. Technology
- 18.3.3. Cancer Type
- 18.3.4. Therapy Type
- 18.3.5. Biomarker Type
- 18.3.6. Application
- 18.3.7. End User
- 18.3.8. Country
- 18.3.8.1. South Africa
- 18.3.8.2. Egypt
- 18.3.8.3. Nigeria
- 18.3.8.4. Algeria
- 18.3.8.5. Rest of Africa
- 18.4. South Africa Personalized Oncology Market
- 18.4.1. Country Segmental Analysis
- 18.4.2. Component
- 18.4.3. Technology
- 18.4.4. Cancer Type
- 18.4.5. Therapy Type
- 18.4.6. Biomarker Type
- 18.4.7. Application
- 18.4.8. End User
- 18.5. Egypt Personalized Oncology Market
- 18.5.1. Country Segmental Analysis
- 18.5.2. Component
- 18.5.3. Technology
- 18.5.4. Cancer Type
- 18.5.5. Therapy Type
- 18.5.6. Biomarker Type
- 18.5.7. Application
- 18.5.8. End User
- 18.6. Nigeria Personalized Oncology Market
- 18.6.1. Country Segmental Analysis
- 18.6.2. Component
- 18.6.3. Technology
- 18.6.4. Cancer Type
- 18.6.5. Therapy Type
- 18.6.6. Biomarker Type
- 18.6.7. Application
- 18.6.8. End User
- 18.7. Algeria Personalized Oncology Market
- 18.7.1. Country Segmental Analysis
- 18.7.2. Component
- 18.7.3. Technology
- 18.7.4. Cancer Type
- 18.7.5. Therapy Type
- 18.7.6. Biomarker Type
- 18.7.7. Application
- 18.7.8. End User
- 18.8. Rest of Africa Personalized Oncology Market
- 18.8.1. Country Segmental Analysis
- 18.8.2. Component
- 18.8.3. Technology
- 18.8.4. Cancer Type
- 18.8.5. Therapy Type
- 18.8.6. Biomarker Type
- 18.8.7. Application
- 18.8.8. End User
- 19. South America Personalized Oncology Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. South America Personalized Oncology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 19.3.1. Component
- 19.3.2. Technology
- 19.3.3. Cancer Type
- 19.3.4. Therapy Type
- 19.3.5. Biomarker Type
- 19.3.6. Application
- 19.3.7. End User
- 19.3.8. Country
- 19.3.8.1. Brazil
- 19.3.8.2. Argentina
- 19.3.8.3. Rest of South America
- 19.4. Brazil Personalized Oncology Market
- 19.4.1. Country Segmental Analysis
- 19.4.2. Component
- 19.4.3. Technology
- 19.4.4. Cancer Type
- 19.4.5. Therapy Type
- 19.4.6. Biomarker Type
- 19.4.7. Application
- 19.4.8. End User
- 19.5. Argentina Personalized Oncology Market
- 19.5.1. Country Segmental Analysis
- 19.5.2. Component
- 19.5.3. Technology
- 19.5.4. Cancer Type
- 19.5.5. Therapy Type
- 19.5.6. Biomarker Type
- 19.5.7. Application
- 19.5.8. End User
- 19.6. Rest of South America Personalized Oncology Market
- 19.6.1. Country Segmental Analysis
- 19.6.2. Component
- 19.6.3. Technology
- 19.6.4. Cancer Type
- 19.6.5. Therapy Type
- 19.6.6. Biomarker Type
- 19.6.7. Application
- 19.6.8. End User
- 20. Key Players/ Company Profile
- 20.1. AstraZeneca PLC
- 20.1.1. Company Details/ Overview
- 20.1.2. Company Financials
- 20.1.3. Key Customers and Competitors
- 20.1.4. Business/ Industry Portfolio
- 20.1.5. Product Portfolio/ Specification Details
- 20.1.6. Pricing Data
- 20.1.7. Strategic Overview
- 20.1.8. Recent Developments
- 20.2. Bristol-Myers Squibb Company
- 20.3. CTOAM
- 20.4. Foundation Medicine, Inc.
- 20.5. Illumina, Inc.
- 20.6. Novartis AG
- 20.7. Thermo Fisher Scientific Inc.
- 20.8. Other Key Players
- 20.1. AstraZeneca PLC
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
Research Design
Our research design integrates both demand-side and supply-side analysis through a balanced combination of primary and secondary research methodologies. By utilizing both bottom-up and top-down approaches alongside rigorous data triangulation methods, we deliver robust market intelligence that supports strategic decision-making.
MarketGenics' comprehensive research design framework ensures the delivery of accurate, reliable, and actionable market intelligence. Through the integration of multiple research approaches, rigorous validation processes, and expert analysis, we provide our clients with the insights needed to make informed strategic decisions and capitalize on market opportunities.
MarketGenics leverages a dedicated industry panel of experts and a comprehensive suite of paid databases to effectively collect, consolidate, and analyze market intelligence.
Our approach has consistently proven to be reliable and effective in generating accurate market insights, identifying key industry trends, and uncovering emerging business opportunities.
Through both primary and secondary research, we capture and analyze critical company-level data such as manufacturing footprints, including technical centers, R&D facilities, sales offices, and headquarters.
Our expert panel further enhances our ability to estimate market size for specific brands based on validated field-level intelligence.
Our data mining techniques incorporate both parametric and non-parametric methods, allowing for structured data collection, sorting, processing, and cleaning.
Demand projections are derived from large-scale data sets analyzed through proprietary algorithms, culminating in robust and reliable market sizing.
Research Approach
The bottom-up approach builds market estimates by starting with the smallest addressable market units and systematically aggregating them to create comprehensive market size projections.
This method begins with specific, granular data points and builds upward to create the complete market landscape.
Customer Analysis → Segmental Analysis → Geographical Analysis
The top-down approach starts with the broadest possible market data and systematically narrows it down through a series of filters and assumptions to arrive at specific market segments or opportunities.
This method begins with the big picture and works downward to increasingly specific market slices.
TAM → SAM → SOM
Research Methods
Desk / Secondary Research
While analysing the market, we extensively study secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and commercial report. Secondary sources that we utilize are not only the public sources, but it is a combination of Open Source, Associations, Paid Databases, MG Repository & Knowledgebase, and others.
- Company websites, annual reports, financial reports, broker reports, and investor presentations
- National government documents, statistical databases and reports
- News articles, press releases and web-casts specific to the companies operating in the market, Magazines, reports, and others
- We gather information from commercial data sources for deriving company specific data such as segmental revenue, share for geography, product revenue, and others
- Internal and external proprietary databases (industry-specific), relevant patent, and regulatory databases
- Governing Bodies, Government Organizations
- Relevant Authorities, Country-specific Associations for Industries
We also employ the model mapping approach to estimate the product level market data through the players' product portfolio
Primary Research
Primary research/ interviews is vital in analyzing the market. Most of the cases involves paid primary interviews. Primary sources include primary interviews through e-mail interactions, telephonic interviews, surveys as well as face-to-face interviews with the different stakeholders across the value chain including several industry experts.
| Type of Respondents | Number of Primaries |
|---|---|
| Tier 2/3 Suppliers | ~20 |
| Tier 1 Suppliers | ~25 |
| End-users | ~25 |
| Industry Expert/ Panel/ Consultant | ~30 |
| Total | ~100 |
MG Knowledgebase
• Repository of industry blog, newsletter and case studies
• Online platform covering detailed market reports, and company profiles
Forecasting Factors and Models
Forecasting Factors
- Historical Trends – Past market patterns, cycles, and major events that shaped how markets behave over time. Understanding past trends helps predict future behavior.
- Industry Factors – Specific characteristics of the industry like structure, regulations, and innovation cycles that affect market dynamics.
- Macroeconomic Factors – Economic conditions like GDP growth, inflation, and employment rates that affect how much money people have to spend.
- Demographic Factors – Population characteristics like age, income, and location that determine who can buy your product.
- Technology Factors – How quickly people adopt new technology and how much technology infrastructure exists.
- Regulatory Factors – Government rules, laws, and policies that can help or restrict market growth.
- Competitive Factors – Analyzing competition structure such as degree of competition and bargaining power of buyers and suppliers.
Forecasting Models / Techniques
Multiple Regression Analysis
- Identify and quantify factors that drive market changes
- Statistical modeling to establish relationships between market drivers and outcomes
Time Series Analysis – Seasonal Patterns
- Understand regular cyclical patterns in market demand
- Advanced statistical techniques to separate trend, seasonal, and irregular components
Time Series Analysis – Trend Analysis
- Identify underlying market growth patterns and momentum
- Statistical analysis of historical data to project future trends
Expert Opinion – Expert Interviews
- Gather deep industry insights and contextual understanding
- In-depth interviews with key industry stakeholders
Multi-Scenario Development
- Prepare for uncertainty by modeling different possible futures
- Creating optimistic, pessimistic, and most likely scenarios
Time Series Analysis – Moving Averages
- Sophisticated forecasting for complex time series data
- Auto-regressive integrated moving average models with seasonal components
Econometric Models
- Apply economic theory to market forecasting
- Sophisticated economic models that account for market interactions
Expert Opinion – Delphi Method
- Harness collective wisdom of industry experts
- Structured, multi-round expert consultation process
Monte Carlo Simulation
- Quantify uncertainty and probability distributions
- Thousands of simulations with varying input parameters
Research Analysis
Our research framework is built upon the fundamental principle of validating market intelligence from both demand and supply perspectives. This dual-sided approach ensures comprehensive market understanding and reduces the risk of single-source bias.
Demand-Side Analysis: We understand end-user/application behavior, preferences, and market needs along with the penetration of the product for specific application.
Supply-Side Analysis: We estimate overall market revenue, analyze the segmental share along with industry capacity, competitive landscape, and market structure.
Validation & Evaluation
Data triangulation is a validation technique that uses multiple methods, sources, or perspectives to examine the same research question, thereby increasing the credibility and reliability of research findings. In market research, triangulation serves as a quality assurance mechanism that helps identify and minimize bias, validate assumptions, and ensure accuracy in market estimates.
- Data Source Triangulation – Using multiple data sources to examine the same phenomenon
- Methodological Triangulation – Using multiple research methods to study the same research question
- Investigator Triangulation – Using multiple researchers or analysts to examine the same data
- Theoretical Triangulation – Using multiple theoretical perspectives to interpret the same data
Custom Market Research Services
We will customise the research for you, in case the report listed above does not meet your requirements.
Get 10% Free Customisation